106
Views
20
CrossRef citations to date
0
Altmetric
Review

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease

Pages 57-64 | Published online: 20 Jan 2011

References

  • TannerCMAstonDAEpidemiology of Parkinson’s disease and akinetic syndromesCurr Opin Neurol20001342710970060
  • MiyasakiJMMartinWSuchowerskyOPractice parameter: initiation of treatment for parkinson’s disease: an evidence-based review Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2002581111711781398
  • PahwaRFactorSALyonsKEPractice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200666798399516606909
  • HoffmanBBLefkowitzRJCatecholamines, sympoathomimetic drugs, and adrenergic receptor antagonistsHardmanJGLimbirdLEGoodman GilmanAGoodman and Gilman’s The Pharmacological Basis of TherapeuticsNew YorkMcGraw-Hill1996199248
  • RajputAZesiewiczTAHauserRAMonoamine oxidase inhibitorsFactorSAWeinerWJParkinson’s Disease: Diagnosis and Clinical ManagementNew YorkDemos Medical Publishing2008499513
  • FowlerCJTiptonKFOn the substrate specificities of the two forms of monoamine oxidaseJ Pharm Pharmacol19843621111156143794
  • RohatagiSBar rettJSdeWittKEMoralesRJIntegrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administrationBiopharm Drug Dispos19971875675849330778
  • DollerHJConnorJDChanges in neostriatal dopamine concentrations in response to levodopa infusionsJ Neurochem1980345126412697373307
  • LewittPAMAO-B inhibitor know-how: back to the pharmNeurology200972151352135719365057
  • GoetzCGStebbinsGTChmuraTATeaching tape for the motor section of the unified Parkinson’s Disease Rating ScaleMov Disord19951032632667544438
  • ShulmanLMGruber-BaldiniALAndersonKEThe clinically important difference on the unified Parkinson’s Disease Rating ScaleArch Neurol2010671647020065131
  • HauserRAFriedlanderJZesiewiczTAA home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesiaClin Neuropharmacol2000232758110803796
  • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study GroupN Engl J Med199332831761838417384
  • PalhagenSHeinonenEHHagglundJSelegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study GroupNeurology19985125205259710028
  • TetrudJWLangstonJWThe effect of deprenyl (selegiline) on the natural history of Parkinson’s diseaseScience198924549175195222502843
  • MyllylaVVSotaniemiKAVuorinenJAHeinonenEHSelegiline in de novo parkinsonian patients: The Finnish StudyMov Disord19938Suppl 1S41S448302307
  • ClarkeAA new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibitionJ Neural Transm200311011125714628190
  • Parkinson Study GroupA controlled trial of rasagiline in early Parkinson disease: the TEMPO studyArch Neurol200259121937194312470183
  • OlanowCWRascolOHauserRA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
  • OlanowCWRascolOHauserRA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
  • HeinonenEHRinneUKSelegiline in the treatment of Parkinson’s diseaseActa Neurol Scand Suppl19891261031112515715
  • LeesAJCurrent controversies in the use of selegiline hydrochlorideJ Neural Transm Suppl1987251571623123602
  • GolbeLILiebermanANMuenterMDDeprenyl in the treatment of symptom fluctuations in advanced Parkinson’s diseaseClin Neuropharmacol198811145553127050
  • WatersCHSethiKDHauserRAZydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyMov Disord200419442643215077240
  • ShoulsonIOakesDFahnSImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Anti-oxidative Therapy of Parkinsonism TrialAnn Neurol200251560461212112107
  • LiebermanANGopinathanGNeophytidesAFooSHDeprenyl versus placebo in Parkinson disease: a double-blind studyNY State J Med19878712646649
  • Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562224124815710852
  • RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily Study): a randomised, double-blind, parallel-group trialLancet2005365946394795415766996
  • ShulmanLMGruber-BaldiniALAndersonKEThe evolution of disability in Parkinson diseaseMov Disord200823679079618361474
  • SchawabRSEnglandACJrParkinson’s disease: rehabilitation aspectsRehabil Lit19612232623613909632
  • HeinonenEHRinneUKTuominenJSelegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatmentActa Neurol Scand Suppl19891261131182515716
  • LarsenJPBoasJThe effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian–Danish 5-year study. Norwegian–Danish Study GroupMov Disord19971221751829087975
  • WebsterDDCritical analysis of the disability in Parkinson’s diseaseMod Treat1968522572825655944
  • CanterCde la TorreRMierMA method of evaluating disabilities in patients with Parkinson’s diseaseJ Nerv Ment Dis196113314314713876261
  • LeesAJComparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease Parkinson’s Disease Research Group of the United KingdomBMJ19953117020160216078555803
  • KluckRMBossy-WetzelEGreenDRNewmeyerDDThe release of cytochrome C from mitochondria: a primary site for bcl-2 regulation of apoptosisScience19972755303113211369027315
  • ShahaniNGourie-DeviMNaliniA(-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patientsAmyotroph Lateral Scler Other Motor Neuron Disord20045317217915512906
  • CarrilloMCMinamiCKitaniKEnhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the ratLife Sci200067557758510993123
  • MaruyamaWYamamotoTKitaniKMechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagilineMech Ageing Dev200011623181191
  • TakahataKShimazuSKatsukiHEffects of selegiline on antioxidant systems in the nigrostriatum in ratJ Neural Transm2006113215115815959853
  • FinbergJPTakeshimaTJohnstonJMCommissiongJWIncreased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitorNeuroreport1998947037079559942
  • MaruyamaWAkaoYCarrilloMCNeuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genesNeurotoxicol Teratol200224567568212200198
  • SharmaSKCarlsonECEbadiMNeuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neuronsJ Neurocytol200332432934314724376
  • EbadiMSharmaSShavaliSThe multiple actions of selegilineProc West Pharmacol Soc200245394112434521
  • BlandiniFNeuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease?CNS Drug Rev200511218319416007239
  • KupschASautterJGotzMEMPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineJ Neural Transm20011088–9985100911716151
  • BlandiniFArmenteroMTFancelluRNeuroprotective effect of rasagiline in a rodent model of Parkinson’s diseaseExp Neurol2004187245545915144871
  • SimonLSzilagyiGBoriZ(-)-D-deprenyl attenuates apoptosis in experimental brain ischaemiaEur J Pharmacol200143023235241
  • SpeiserZMaykAEliashSCohenSStudies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the ratJ Neural Transm199910678593606
  • HolfordNHChanPLNuttJGParkinson Study GroupDisease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatmentsJ Pharmacokinet Pharmacodyn200633328131116625427
  • D’AgostinoRBThe delayed-start study designN Engl J Med2009361131304130619776413
  • OlanowCWRascolOThe delayed-start study in Parkinson disease: can’t satisfy everyoneNeurology201074141149115020368635
  • AhlskogJEUittiRJRasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?Neurology201074141143114820368634
  • AhlskogJEUittiRJReply to Drs. Olanow and RascolNeurology20107414115120368636
  • SampaioCFerreiraJJParkinson disease: ADAGIO trial hints that rasagiline slows disease progressionNat Rev Neurol20106312612820212427
  • MehtaSHMorganJCSethiKDDoes rasagiline have a disease-modifying effect on Parkinson’s disease?Curr Neurol Neurosci Rep201010641341620711692
  • HeinonenEHSafety of selegiline (deprenyl) in the treatment of Parkinsons diseaseDrug Safety1998191119673855
  • MyllylaVVSotaniemiKMaki-IkolaORole of selegiline in combination therapy of Parkinson’s diseaseNeurology199612476 Suppl 3S200S2098959989
  • ElizanTSMorosDAYahrMDEarly combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson’s disease: experience in 26 patients receiving combined therapy for 26 monthsArch Neurol199148131341898848
  • GolbeLILong-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson’s diseaseNeurology1989398110911112503769
  • WatersCHSide effects of selegiline (eldepryl)J Geriatr Psychiatry Neurol19925131341571071
  • ChurchyardAMathiasCJBoonkongchuenPLeesAJAutonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry19976322282349285463
  • GoetzCGSchwidSREberlySWParkinson Study Group TEMPO and PRESTO InvestigatorsSafety of rasagiline in elderly patients with Parkinson diseaseNeurology20066691427142916682679
  • Leegwater-KimJBortanEThe role of rasagiline in the treatment of Parkinson’s diseaseClin Interv Aging2010514915620517484
  • MarleyEBlackwellBInteractions of monoamine oxidase inhibitors, amines, and foodstuffsAdv Pharmacol Chemother197081853494947578
  • ElsworthJDGloverVReynoldsGPDeprenyl administration in man: a selective monoamine oxidase B inhibitor without the ’cheese effect’Psychopharmacology (Berl)1978571333896466
  • SchulzRTyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegilineClin Pharmacol Ther19894655282510962
  • HeinonenEHLammintaustaRA review of the pharmacology of selegilineActa Neurol Scand Suppl199113644591686954
  • GorenTClinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagilineJ Clin Pharmacol201050121420142820445015
  • deMarcaidaJAEffects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagilineMov Disord20062110171616856145
  • SternbachHThe serotonin syndromeAm J Psychiatry199114867057132035713
  • RadomskiJWDursunSMReveleyMAKutcherSPAn exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteriaMed Hypotheses200055321822410985912
  • OatesJASjoerdsmaANeurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitorNeurology1960101076107813730138
  • MasonPJMorrisVABalcezakTJSerotonin syndrome presentation of 2 cases and review of the literatureMedicine (Baltimore)200079420120910941349
  • WatersCHFluoxetine and selegiline: lack of significant interactionCan J Neurol Sci19942132592618000982
  • FeighnerJPBoyerWFTylerDLNeborskyRJAdverse consequences of fluoxetine-MAOI combination therapyJ Clin Psychiatry19905162222252347858
  • RichardIHKurlanRTannerCSerotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study GroupNeurology1997484107010779109902
  • HilliJKorhonenTLaineKLack of clinically significant interactions between concomitantly administered rasagiline and escitalopramProg Neuropsychopharmacol Biol Psychiatry20093381526153219733607
  • EvansAHKatzenschlagerRPaviourDPunding in Parkinson’s disease: its relation to the dopamine dysregulation syndromeMov Disord200419439740515077237
  • EvansAHLawrenceADCresswellSACompulsive use of dopaminergic drug therapy in Parkinson’s disease: reward and anti-rewardMov Disord201025786787620461804
  • EvansAHLawrenceADPottsJFactors influencing susceptibility to compulsive dopaminergic drug use in Parkinson diseaseNeurology200565101570157416301483
  • GiovannoniGO’SullivanJDTurnerKHedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapiesJ Neurol Neurosurg Psychiatry200068442342810727476
  • LawrenceADEvansAHLeesAJCompulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry?Lancet Neurol200321059560414505581
  • GrossetDEuropean PD Therapy Compliance Study GroupTherapy adherence issues in Parkinson’s diseaseJ Neurol Sci201028912115118
  • GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter european studyMov Disord200924682683219191340
  • OlanowCWObesoJAStocchiFDrug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s diseaseNat Clin Pract Neurol20062738239216932589
  • StocchiFVaccaLRuggieriSOlanowCWIntermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyArch Neurol200562690591015956161
  • GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter European studyMov Disord200924682683219191340
  • ZesiewiczTASullivanKLArnulfIPractice parameter: treatment of nonmotor symptoms of Parkinson disease Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2010741192493120231670
  • Gruber-BaldiniALYeJAndersonKEShulmanLMEffects of optimism/pessimism and locus of control on disability and quality of life in Parkinson’s diseaseParkinsonism Relat Disord200915966566919362510
  • BrysonHMMilneRJChrispPSelegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson’s diseasePharmacoeconomics19922211813610146952
  • LyonsKEFriedmanJHHermanowiczNOrally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effectsClin Neuropharmacol201033151019855267
  • BiglanKMSchwidSEberlySRasagiline improves quality of life in patients with early Parkinson’s diseaseMov Disord200621561662316450340
  • JostWHKlasserMReichmannHRasagiline in daily clinical use: results of a treatment study of Parkinson patients with a combination treatmentFortschr Neurol Psychiatr2008761059459918833504